![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, October 07, 2013 9:01:03 AM
October 7, 2013
07:01 EDT GWPH GW Pharmaceuticals price target raised to $65 from $22 at Lazard Capital
Lazard Capital raised its price target significantly for GW Pharmaceuticals to $65 citing the company's orphan program for epilepsy. The firm calls GW one of the most compelling opportunities its ever seen and keeps a Buy rating on the stock.
www.theflyonthewall.com/permalinks/entry.php/GWPHid1896615/GWPH-GW-Pharmaceuticals-price-target-raised-to--from--at-Lazard-Capital
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM